Innovative approaches to the management of ascites in cirrhosis

Bruno, 2013, Am J Gastroenterol, 108, 1112, 10.1038/ajg.2013.110 Balcar, 2022, Baveno Cooperation: an EASL consortium. Risk of further decompensation/mortality in patients with cirrhosis and ascites as the first single decompensation event, JHEP Rep, 4 Adebayo, 2019, Refractory ascites in liver cirrhosis, Am J Gastroenterol, 114, 40, 10.1038/s41395-018-0185-6 Iwakiri, 2021, Portal hypertension in cirrhosis: pathophysiological mechanisms and therapy, JHEP Rep, 3 Engelmann, 2021, Pathophysiology of decompensated cirrhosis: portal hypertension, circulatory dysfunction, inflammation, metabolism and mitochondrial dysfunction, J Hepatol, 75, S49, 10.1016/j.jhep.2021.01.002 Jalan, 2021, New clinical and pathophysiological perspectives defining the trajectory of cirrhosis, J Hepatol, 75, S14, 10.1016/j.jhep.2021.01.018 Ripoll, 2007, Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis, Gastroenterology, 133, 481, 10.1053/j.gastro.2007.05.024 Villanueva, 2019, β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial, Lancet, 393, 1597, 10.1016/S0140-6736(18)31875-0 Levy, 2019, Prevention of decompensation in cirrhosis: a new youth for β blockers, Lancet, 393, 1571, 10.1016/S0140-6736(19)30736-6 Groszmann, 2005, Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis, N Engl J Med, 353, 2254, 10.1056/NEJMoa044456 Abd Elrahim, 2018, Efficacy of carvedilol versus propranolol versus variceal band ligation for primary prevention of variceal bleeding, Hepatol Int, 12, 75, 10.1007/s12072-017-9835-9 Villanueva, 2022, Carvedilol-IPD-MA-group and the Baveno Cooperation: an EASL Consortium. Carvedilol reduces the risk of decompensation and mortality in patients with compensated cirrhosis in a competing-risk meta-analysis, J Hepatol, 77, 1014, 10.1016/j.jhep.2022.05.021 Sharma, 2022, Non-hemodynamic effects of beta-blockers in decompensated cirrhosis. In search of an ideal marker?, Clin Gastroenterol Hepatol, 20, E1511, 10.1016/j.cgh.2021.07.050 de Franchis, 2022, Baveno VII - renewing consensus in portal hypertension, J Hepatol, 76, 959, 10.1016/j.jhep.2021.12.022 Dajti, 2022, A combined Baveno VII and spleen stiffness algorithm to improve the non-invasive diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease, Am J Gastroenterol, 117, 1825, 10.14309/ajg.0000000000001887 Jachs, 2022, The sequential application of Baveno VII criteria and VITRO score improves diagnosis of clinically significant portal hypertension, Clin Gastroenterol Hepatol, 22, S1542 Fernández, 2019, Casulleras M.,et al. Effects of albumin treatment on systemic and portal hemodynamics and systemic inflammation in patients with decompensated cirrhosis, Gastroenterology, 157, 149, 10.1053/j.gastro.2019.03.021 Caraceni, 2018, Long-term albumin administration in decompensated cirrhosis (ANSWER): an open-label randomised trial, Lancet, 391, 2417, 10.1016/S0140-6736(18)30840-7 Caraceni, 2021, On-treatment serum albumin level can guide long-term treatment in patients with cirrhosis and uncomplicated ascites, J Hepatol, 74, 340, 10.1016/j.jhep.2020.08.021 Di Pascoli, 2019, Long-term administration of human albumin improves survival in patients with cirrhosis and refractory ascites, Liver Int, 39, 98, 10.1111/liv.13968 Solà, 2018, Midodrine and albumin for prevention of complications in patients with cirrhosis awaiting liver transplantation. A randomized placebo-controlled trial, J Hepatol, 69, 1250, 10.1016/j.jhep.2018.08.006 Caraceni, 2022, Long-term albumin treatment in patients with cirrhosis and ascites, J Hepatol, 76, 1306, 10.1016/j.jhep.2022.03.005 Saffo, 2018, SGLT2 inhibitors and cirrhosis: a unique perspective on the co-management of diabetes mellitus and ascites, Clin Liver Dis, 11, 141, 10.1002/cld.714 Montalvo-Gordon, 2020, Sodium-glucose cotransporter 2 inhibitors ameliorate ascites and peripheral edema in patients with cirrhosis and diabetes, Hepatology, 72, 1880, 10.1002/hep.31270 Kalambokis, 2021, Empagliflozin eliminates refractory ascites and hepatic hydrothorax in a patient with primary biliary cirrhosis, Am J Gastroenterol, 116, 618, 10.14309/ajg.0000000000000995 Gao, 2021, SGLT2 Inhibitors: a new dawn for recurrent/refractory cirrhotic ascites, J Clin Transl Hepatol, 9, 795 Biggins, 2021, Diagnosis, evaluation and management of ascites, spontaneous bacterial peritonitis and hepatorenal syndrome: 2021 practice guidance by the American association for the study of liver diseases, Hepatology, 74, 1014, 10.1002/hep.31884 Salerno, 2007, Transjugular intra-hepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data, Gastroenterology, 133, 825, 10.1053/j.gastro.2007.06.020 Busk, 2017, Effects of transjugular intrahepatic portosystemic shunt (TIPS) on blood volume distribution in patients with cirrhosis, Dig Liver Dis, 49, 1353, 10.1016/j.dld.2017.06.011 Liu, 2021, Advances in cirrhotic cardiomyopathy, Curr Opin Gastroenterol, 37, 187, 10.1097/MOG.0000000000000733 Billey, 2019, A prospective study identifying predictive factors of cardiac decompensation after transjugular intrahepatic portosystemic shunt: the Toulouse Algorithm, Hepatology, 70, 1928, 10.1002/hep.30934 Modha, 2017, Symptomatic heart failure after transjugular intrahepatic portosystemic shunt placement: incidence, outcomes, and predictors, Cardiovasc Interv Radiol, 41, 564, 10.1007/s00270-017-1848-1 Tripathi, 2020, Transjugular intrahepatic portosystemic stent-shunt in the management of portal hypertension, Gut, 69, 1173, 10.1136/gutjnl-2019-320221 Boike, 2022, Advancing Liver Therapeutic Approaches (ALTA) Consortium. North American practice-based recommendations for transjugular intrahepatic portosystemic shunts in portal hypertension, Clin Gastroenterol Hepatol, 20, 1636, 10.1016/j.cgh.2021.07.018 Fagiuoli, 2017, Consensus conference on TIPS management: techniques, indications, contraindications, Dig Liver Dis, 49, 121, 10.1016/j.dld.2016.10.011 Deltenre, 2023, The role of transjugular intrahepatic portosystemic shunt in patients with cirrhosis and ascites: recent evolution and open questions, Hepatology, 77, 640, 10.1002/hep.32596 Schepis, 2018, Under-dilated TIPS associate with efficacy and reduced encephalopathy in a prospective, non-randomized study of patients with cirrhosis, Clin Gastroenterol Hepatol, 16, 1153, 10.1016/j.cgh.2018.01.029 Praktiknjo, 2021, Controlled under-dilation using novel VIATORR® controlled expansion stents improves survival after transjugular intrahepatic portosystemic shunt implantation, JHEP Rep, 3 Bureau, 2021, The use of rifaximin in the prevention of overt hepatic encephalopathy after transjugular intrahepatic portosystemic shunt: a randomized controlled trial, Ann Intern Med, 174, 633, 10.7326/M20-0202 Seifert, 2021, Recurrence of hepatic encephalopathy after TIPS: effective prophylaxis with combination of lactulose and rifaximin, J Clin Med, 10, 4763 de Wit, 2020, BMJ Open Gastroenterol, 7, 10.1136/bmjgast-2020-000531 Li, 2021, Long-term survival prediction for transjugular intrahepatic portosystemic shunt in severe cirrhotic ascites: assessment of ten prognostic models, Eur J Gastroenterol Hepatol, 33, 1547, 10.1097/MEG.0000000000001890 Bettinger, 2021, Refining prediction of survival after TIPS with the novel Freiburg index of post-TIPS survival, J Hepatol, 74, 1362, 10.1016/j.jhep.2021.01.023 Bureau, 2011, Serum bilirubin and platelet count: a simple predictive model for survival in patients with refractory ascites treated by TIPS, J Hepatol, 54, 901, 10.1016/j.jhep.2010.08.025 Kraglund, 2021, External validation of the Freiburg index of post-TIPS survival, J Hepatol, 75, 746, 10.1016/j.jhep.2021.04.027 Wang, 2021, Freiburg index of post-TIPS survival: the first score for individual prediction and a complementary tool for risk stratification, J Hepatol, 75, 747, 10.1016/j.jhep.2021.05.042 Bureau, 2017, Transjugular intrahepatic portosystemic shunts with covered stents increase transplant-free survival of patients with cirrhosis and recurrent ascites, Gastroenterology, 152, 157, 10.1053/j.gastro.2016.09.016 Bureau, 2017, Alfapump® system vs. large volume paracentesis for refractory ascites: a multicenter randomized controlled study, J Hepatol, 67, 940, 10.1016/j.jhep.2017.06.010 Bellot, 2013, Automated low flow pump system for the treatment of refractory ascites: a multi-center safety and efficacy study, J Hepatol, 58, 922, 10.1016/j.jhep.2012.12.020 Thomas, 2015, Automated low flow pump system for the treatment of refractory ascites: a single-center experience, Langenbeck’s Arch Surg, 400, 979, 10.1007/s00423-015-1356-1 Stirnimann, 2017, Treatment of refractory ascites with an automated low-flow ascites pump in patients with cirrhosis, Aliment Pharmacol Ther, 46, 981, 10.1111/apt.14331 Solbach, 2018, Automated low-flow ascites pump in a real-world setting: complications and outcomes, Eur J Gastroenterol Hepatol, 30, 1082, 10.1097/MEG.0000000000001149 Wong, 2020, Improvement in quality of life and decrease in large-volume paracentesis requirements with the automated low-flow ascites pump, Liver Transpl, 26, 651, 10.1002/lt.25724 Will, 2020, Transjugular intrahepatic portosystemic shunt and alfapump® system for refractory ascites in liver cirrhosis: outcomes and complications, United Eur Gastroenterol J, 8, 961, 10.1177/2050640620938525 Lepida, 2019, Systematic review with meta-analysis: automated low-flow ascites pump therapy for refractory ascites, Aliment Pharmacol Ther, 50, 978, 10.1111/apt.15502 Solà, 2017, Effects of alfapump™ system on kidney and circulatory function in patients with cirrhosis and refractory ascites, Liver Transpl, 23, 583, 10.1002/lt.24763 Aagaard, 2022, Consensus care recommendations for alfapump®in cirrhotic patients with refractory or recurrent ascites, BMC Gastroenterol, 22, 111, 10.1186/s12876-022-02173-5 Stepanova, 2018, Patients with refractory ascites treated with alfapump® system have better health-related quality of life as compared to those treated with large volume paracentesis: the results of a multicenter randomized controlled study, Qual Life Res, 27, 1513, 10.1007/s11136-018-1813-8 Nguyen-Khac, 2021, Combined treatment of refractory ascites with an alfapump® plus hernia repair in the same surgical session: a retrospective, multicentre, European pilot study in cirrhotic patients, J Visc Surg, 158, 27 Will, 2022, Current treatment options of refractory ascites in liver cirrhosis - a systematic review and meta-analysis, Dig Liver Dis, 54, 1007, 10.1016/j.dld.2021.12.007 Stirnimann, 2022, Final safety and efficacy results from a 106 real-world patients registry with an ascites-mobilizing pump, Liver Int, 42, 2247, 10.1111/liv.15337 Weil-Verhoeven, 2022, Alfapump® implantable device in the management of refractory ascites: an update, World J Hepatol, 14, 1344, 10.4254/wjh.v14.i7.1344 Reverter, 2019, Metabolomics discloses potential biomarkers to predict the acute HVPG response to propranolol in patients with cirrhosis, Liver Int, 39, 705, 10.1111/liv.14042 Mandorfer, 2020, Noninvasive diagnostics for portal hypertension: a comprehensive review, Semin Liver Dis, 40, 240, 10.1055/s-0040-1708806 Bajaj, 2021, Admission urinary and serum metabolites predict renal outcomes in hospitalized patients with cirrhosis, Hepatology, 74, 2699, 10.1002/hep.31907 Poyan Mehr, 2018, De novo NAD(+) biosynthetic impairment in acute kidney injury in humans, Nat Med, 24, 1351, 10.1038/s41591-018-0138-z Piano, 2021, Metabolomics to predict acute kidney injury in cirrhosis, Hepatology, 74, 2339, 10.1002/hep.32060